Sakiyama Masayuki, Matsuo Hirotaka, Takada Yuzo, Nakamura Takahiro, Nakayama Akiyoshi, Takada Tappei, Kitajiri Shin-Ichiro, Wakai Kenji, Suzuki Hiroshi, Shinomiya Nariyoshi
Department of Integrative Physiology and Bio-Nano Medicine, National Defense Medical College, Tokorozawa, Japan; Department of Dermatology, National Defense Medical College, Tokorozawa, Japan.
Drug Metab Pharmacokinet. 2014;29(6):490-2. doi: 10.2133/dmpk.DMPK-14-SC-041. Epub 2014 May 27.
ATP-binding cassette transporter, sub-family G, member 2 (ABCG2/BCRP) is a xenobiotic transporter and also regulates serum uric acid levels as a urate transporter. We have shown that the severity of ABCG2 dysfunction can be estimated by simple genotyping of two dysfunctional variants, Q126X (rs72552713) and Q141K (rs2231142). This genotyping method is widely accepted for the risk analysis of hyperuricemia/gout, but there is no report on ethnic differences in ABCG2 dysfunctions. Here, we estimated ABCG2 dysfunctions by its genotype combination (Q126X and Q141K) and compared them in three different ethnic groups (500 Japanese, 200 Caucasians and 100 African-Americans). The minor allele frequencies of Q126X and Q141K in Japanese (0.025 and 0.275, respectively) were significantly higher than those in Caucasians (0.005 and 0.085, respectively) and African-Americans (0 and 0.090, respectively). Additionally, the rates of mild, moderate and severe ABCG2 dysfunctions in Japanese (35.4%, 12.4% and 1.6%, respectively) were higher than those in Caucasians (14.0%, 2.5% and 0%, respectively) and African-Americans (14.0%, 2.0% and 0%, respectively). Because ABCG2 dysfunctional diplotypes were commonly observed in both Caucasians (16.5%) and African-Americans (16.0%), the genotyping of the two ABCG2 dysfunctional variants is useful for evaluating individual differences in the ABCG2 dysfunction which affect the pharmacokinetics of substrate drugs and hyperuricemia risk in all three ethnic groups.
ATP结合盒转运体G亚家族成员2(ABCG2/BCRP)是一种外源性物质转运体,同时作为尿酸盐转运体调节血清尿酸水平。我们已经表明,ABCG2功能障碍的严重程度可以通过对两个功能障碍变异体Q126X(rs72552713)和Q141K(rs2231142)进行简单基因分型来估计。这种基因分型方法在高尿酸血症/痛风的风险分析中被广泛接受,但尚无关于ABCG2功能障碍种族差异的报道。在此,我们通过ABCG2基因型组合(Q126X和Q141K)估计其功能障碍,并在三个不同种族群体(500名日本人、200名白种人和100名非裔美国人)中进行比较。Q126X和Q141K在日本人中的次要等位基因频率(分别为0.025和0.275)显著高于白种人(分别为0.005和0.085)和非裔美国人(分别为0和0.090)。此外,日本人中轻度、中度和重度ABCG2功能障碍的发生率(分别为35.4%、12.4%和1.6%)高于白种人(分别为14.0%、2.5%和0%)和非裔美国人(分别为14.0%、2.0%和0%)。由于ABCG2功能障碍单倍型在白种人(16.5%)和非裔美国人(16.0%)中普遍存在,对两个ABCG2功能障碍变异体进行基因分型有助于评估影响底物药物药代动力学和所有三个种族群体高尿酸血症风险的ABCG2功能障碍个体差异。